Cytosorbents corp (CTSO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Cash flows from operating activities:
Net loss

-17,834

-19,265

-20,719

-16,839

-19,112

-17,211

-14,955

-14,004

-9,917

-8,460

-10,219

-10,181

-11,452

-11,763

-10,204

-11,035

-6,596

-9,477

-11,124

-9,775

-13,063

-9,321

-4,996

-4,462

-4,023

-4,677

-4,546

-4,233

-3,865

-3,663

0

0

0

Adjustments to reconcile net loss to net cash used by operating activities:
Contributed technology expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Consulting expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Management unit expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Expense for issuance of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Expense for issuance of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

346

325

288

63

0

0

0

Amortization of deferred compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Common stock issued as inducement to convert convertible notes payable and accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Non-cash compensation

1,389

1,173

1,220

739

992

947

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

180

180

90

155

65

65

65

0

0

0

0

0

Depreciation and amortization

624

581

547

548

472

390

313

232

211

218

213

195

192

161

143

137

124

112

73

64

67

65

87

78

69

64

70

64

58

54

0

0

0

Amortization of debt costs

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

198

281

292

215

311

279

270

305

471

0

0

0

Gain on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Gain on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Interest expense paid with Series B Preferred Stock in connection with conversion of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Abandoned patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

Bad debt

66

72

-46

-39

24

14

13

6

3

0

69

69

66

65

0

0

0

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Stock-based compensation

2,167

1,666

2,748

2,219

4,140

4,437

4,326

5,012

3,745

3,313

3,883

3,048

2,741

2,756

846

835

425

382

805

737

702

695

0

0

0

-

-

-

-

-

-

-

-

Change in warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-3,371

-

1,509

503

4,442

2,118

-208

26

-316

0

0

0

0

-

-

-

-

Foreign currency transaction loss

-625

-350

-1,292

-445

-1,536

-784

-311

146

1,659

1,454

687

412

-436

-358

1

1

293

-386

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Grants and accounts receivable

2,277

642

-79

552

1,118

1,847

1,364

883

482

649

945

1,131

1,079

889

852

444

67

-131

62

250

433

412

371

246

212

401

141

40

74

15

0

0

0

Inventories

754

1,284

1,035

737

567

56

-299

-105

-192

-57

30

-152

-70

-340

-241

25

281

671

936

746

548

308

24

-172

-408

-436

-263

-58

86

251

0

0

0

Prepaid expenses and other current assets

1,302

953

565

566

334

731

278

3

-93

76

116

221

265

-187

-151

-113

44

-178

166

-68

-22

108

67

209

98

129

41

9

47

432

0

0

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

7

7

11

4

20

21

-2

6

-18

-18

0

-9

0

0

0

Accounts payable and accrued expenses

1,433

1,424

1,029

1,913

368

1,704

887

-412

146

-168

-16

801

1,378

1,632

986

988

411

-83

400

32

454

497

-29

60

-85

118

102

249

68

147

0

0

0

Accrued interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

-3

-5

-117

-271

-432

5

117

272

0

0

0

-

-

-

-

Net cash used by operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-8,348

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used by operating activities

-15,730

-16,758

-15,341

-12,769

-12,873

-10,839

-8,542

-8,089

-6,680

-6,460

0

0

0

-

-

-

-

-

-

-

-

-

-

-3,916

-3,479

-3,489

-3,148

-3,230

-3,353

-3,616

0

0

0

Cash flows from investing activities:
Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Purchases of property and equipment

641

698

733

634

721

671

906

1,229

1,162

990

564

272

175

140

262

309

335

403

360

290

235

153

94

70

57

38

53

41

22

19

0

0

0

Payments for patent costs

913

821

706

766

800

848

872

812

783

687

629

569

517

454

453

406

274

239

252

197

245

214

248

226

182

177

16

6

7

18

0

0

0

Proceeds from sale of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,430

8,681

7,187

5,991

4,745

0

0

0

-

-

0

0

0

0

0

0

Purchases of short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,735

5,678

3,277

5,630

4,185

6,689

7,346

4,745

4,745

0

0

0

0

0

0

0

0

Loan receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Net cash used by investing activities

-1,554

-1,520

-1,440

-1,401

-1,522

-1,520

-1,778

-2,041

-1,945

-1,678

0

0

0

-

-

-

-

-

-

-

-

-

-

-5,042

-4,985

-216

-69

-48

-29

-38

0

0

0

Cash flows from financing activities:
Net cash used by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-161

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from long-term debt

-

-

-

-

-

666

666

666

5,666

5,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of long-term debt

-

-

-

-

-

666

666

666

666

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt acquisition costs

-

-

-

-

-

-

-

0

149

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of preferred stock, net of related issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Equity contributions - net of fees incurred

18,416

673

209

2,223

8,079

14,126

15,821

15,262

19,726

13,679

0

0

0

-

-

-

-

9,524

0

0

0

-

-

-

11,501

2,199

2,049

2,299

2,950

3,500

0

0

0

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from borrowing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,843

1,263

1,098

0

700

0

0

0

Proceeds from subscription receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Proceeds from exercise of stock options

642

739

994

1,189

1,913

2,206

2,351

1,993

1,119

591

219

146

94

118

127

165

425

410

381

297

67

109

90

66

71

20

30

25

10

10

0

0

0

Proceeds from exercise of warrants

0

1,768

1,768

1,815

3,033

1,280

1,873

1,911

693

853

275

215

237

65

483

912

1,115

1,705

1,428

974

749

156

0

139

139

139

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,656

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

24,054

8,177

7,880

5,228

13,027

17,465

19,897

19,019

26,389

20,123

0

0

0

-

-

-

-

-

-

-

-

-

-

12,002

13,555

4,202

3,483

3,423

2,960

4,210

0

0

0

Effect of exchange rates on cash

-28

-35

-31

1

-74

-58

-66

-7

86

92

81

59

147

-1

33

28

-27

9

-143

-30

-106

-1

42

-34

-40

-43

24

-15

-15

-12

0

0

0

Net change in cash and cash equivalents

6,741

-10,136

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

17,849

-

9,025

7,731

-297

-71

-1,010

653

-6,881

1,711

6,952

3,138

4,002

1,422

-1,916

3,007

5,050

453

288

128

-437

542

0

0

0

Supplemental disclosure of cash flow information:
Cash paid during the period for interest

1,150

1,059

956

946

857

891

894

822

791

634

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid during the period for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

-

-

0

0

0

0

0

0

0

0

0

0

Supplemental disclosure of non-cash financing activities
Fair value of warrant liability upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Fair value of warrant liability upon issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

Debt discount in connection with issuance of convertible debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

331

330

188

-0

87

0

0

0

Settlement of accrued bonuses with restricted stock units

328

425

425

425

590

545

545

545

444

207

207

207

144

0

0

0

0

-

-

-

-

7

22

46

46

49

45

44

69

247

0

0

0

Equity contribution proceeds in transit

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Note payable principal and interest conversion to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,226

540

830

830

0

0

0

0

Issuance of management units in settlement of cost of raising capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Change in fair value of management units for cost of raising capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Issuance of common stock in exchange for stock subscribed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Costs paid from proceeds in conjunction with issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,019

903

903

903

748

748

748

748

0

0

0

0

0

0

0

0

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,266

4,437

3,681

2,923

2,395

2,368

2,473

2,433

2,511

0

0

0

Net effect of conversion of common stock to preferred stock prior to merger

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0